Kiran Reddy Kanubaddi

Kiran Reddy Kanubaddi

Auto-generated profile, based on publicly available information

Kiran Reddy Kanubaddi

Department of Life Science and Institute of Biotechnology National Dong Hwa University Hualien 97401 Taiwan

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 August 2019 in Advanced Functional Materials
Verified
Journal Article
Closed access
PDF file
Ranjith KankalaRanjith Kankala
Ranjith Kankala
Hongbo ZhangHongbo Zhang
Hongbo Zhang
CLChenguang Liu
Chenguang Liu
KKKiran Reddy Kanubaddi
Kiran Reddy Kanubaddi
CLChia‐Hung Lee
Chia‐Hung Lee
ACAi-Zheng Chen
Ai-Zheng Chen

1 December 2018 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
KKKiran Reddy Kanubaddi
Kiran Reddy Kanubaddi
SYShin-Han Yang
Shin-Han Yang
WLWei Wu Li
Wei Wu Li
CLChia-Hung Lee
Chia-Hung Lee
Ching-Feng WengChing-Feng Weng
Ching-Feng Weng
Alzheimer’s disease (AD), an age-related neurodegenerative disease, the most common causes of dementia is a multifactorial pathology categorized by a complex etiology. Numerous nutraceuticals have been clinically evaluated, but some of the trials failed. However, natural compounds have some limitations due to their poor bioavailability, ineffective capability to cross the blood–brain barrier, or less therapeutic effects on AD. To overcome these disadvantages, nanoparticle-conjugated natural products could promote the bioavailability and enhance the therapeutic efficacy of AD when compared with a naked drug. This application generates and implements new prospect for drug discovery in neurodegenerative diseases. In this article, we confer AD pathology, review natural products in clinical trials, and ascertain the importance of nanomedicine coupled with natural compounds for AD.